Testosterone, 4-hydroxyandrostenedione, and finasteride affect blood clotting differently in stressed heart conditions.
11 citations
,
January 1991 in “Urology” This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.
4 citations
,
May 2019 in “Biology open” This study found that while testosterone administration reduced myocardial damage in gonadectomized rats after ischemia/reperfusion injury, Finasteride led to greater improvements, whereas 4-hydroxyandrostenedione worsened outcomes.
7 citations
,
April 2019 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that 11α-hydroxyprogesterone is a potent inhibitor of 11βHSD2 in vitro and may serve as a precursor to unique C11α-hydroxy steroids in prostate cancer tissue.
36 citations
,
October 2009 in “Journal of Investigative Dermatology” This study suggests that in SZ95 sebocytes, a pathway for DHT biosynthesis does not require testosterone as an intermediate, potentially impacting the treatment of androgen-sensitive skin conditions.